

Client/Sending Facility: LABCORP OF AMERICA CMBP 1912 ALEXANDER DR RTP, NC 27709

Ph: (919)361-7700

Fax: (919) 361-7296 NCB-13

LCLS Specimen Number: 106-225-9013-0 Account Number: 90001555

Patient Name: **REPORT, SAMPLE** Ordering Physician:

Date of Birth: 04/08/1991 Specimen Type: **AMNIOTIC FLUID**

Gender: F Client Reference:

Patient ID: Date Collected: 04/15/2024

Lab Number: YU24-40007 G Date Received: 04/15/2024

Indications: cystic hygroma Date Reported: 05/10/2024

Test: Direct Prenatal SNP CMA

Genotyping Targets: 2772571 Array Type: SNP

MICROARRAY RESULT: NORMAL FEMALE

INTERPRETATION:

arr(1-22,X)x2

The whole genome chromosome SNP microarray (Reveal) analysis was normal. No significant DNA copy number changes or copy neutral regions within the 2.77 million region specific SNP and structural targets were detected under the present reporting criteria indicated below.

Maternal cell contamination studies will be reported under separate cover, if ordered.

Methodology:

SNP microarray analysis was performed using the Cytoscan ® HD Accel platform which uses 2,029,441 nonpolymorphic copy number probes and 743,130 SNP probes for LOH/AOH analysis and relationship assessment. The array has an average intragenic spacing of 0.818 kb and average intergenic spacing of 1.51 kb. Total genomic DNA was extracted from the sample type provided, digested with Xcel, and then ligated to Xcel adaptors. PCR products were purified and quantified. Purified DNA was fragmented, biotin labeled, and hybridized to the Cytoscan ® HD Accel Gene Chip. Data were analyzed using Chromosome Analysis Suite. The analysis is based on the GRCh37/hg19 assembly. This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug administration.

Positive evaluation criteria include:

- \star DNA copy number loss of >1 Mb or gain >2 Mb outside known clinically significant regions with at least one OMIM gene.
- * DNA copy gain/loss within or including a known clinically significant gene of 25 kb or greater.
- * UPD testing is recommended for patient results demonstrating a long contiguous region of homozygosity in a single chromosome of >20 Mb interstitially or >10 Mb telomerically (15 and 8 Mb, respectively, for imprinted chromosomes).
- * Contiguous homozygosity of >8 Mb within multiple chromosomes suggests common descent. These regions of potential recessive allele risk are designated.
- * A high level of allele homozygosity due to numerous contiguous short runs (associated with a geographically or socially limited gene pool) is reported at the 99th percentile.
- * Triploid DNA normalizes to 2 copies in array analysis, but is detectable in this allele specific SNP microarray by the characteristic 2:1 allele ratios and pattern generated within each autosome.

SNP chromosomal microarray cannot detect:

- * Truly balanced chromosome alterations
- * Sequence variants



Client/Sending Facility: LABCORP OF AMERICA **CMBP** 1912 ALEXANDER DR RTP, NC 27709

Ph: (919)361-7700 Fax: (919) 361-7296 NCB-13

LCLS Specimen Number: 106-225-9013-0 Account Number: 90001555

> Patient Name: **REPORT, SAMPLE** Ordering Physician:

Date of Birth: 04/08/1991 Specimen Type: AMNIOTIC FLUID

Gender: F Client Reference:

Patient ID: Date Collected: 04/15/2024 Lab Number: YU24-40007 G Date Received: 04/15/2024

* Small insertions and deletions (indels)

- * Changes in regions not represented by probes on the array
- * Tetraploidy
- * Low level mosaicism
- * Whole chromosome uniparental heterodisomy without parental specimens
- * Imbalances in the mitochondrial genome

Single gene partial or intragenic copy number variants (CNVs) detected by an independent technology such as next generation sequencing (NGS) may not be detectable by microarray. The ability to detect the CNV is dependent on size and probe coverage. The threshold for mosaicism is variable, depending on the size of the segment and array quality. Empiric studies have detected mosaicism for trisomy of a whole autosome below 10.0%. CNVs that are known to be common in the population may not be reported.

GLORIA HASKELL, PHD, FACMG

Anjen Chenn, M.D., Ph.D. Medical Director

Technical component performed by Laboratory Corporation of America Holdings,

1904 TW Alexander Drive, RTP, NC, 27709-0153 (800) 345-4363

Professional Component performed by LabCorp CLIA 34D1008914, 3502 Stonegate Dr., Chapel Hill, NC 27516. Medical Director, Anjen Chenn, M.D., PhD. Integrated Genetics is a brand used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings.

This document contains private and confidential health information protected by state and federal law.

If you have received this document in error, please call 800-533-0567.

Gloria Hashell